Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | CALCA | P06881 | 8/20 | 0.44 |
| ▸ | CALCRL | Q16602 | 11/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3546810 | 1.00 | ACACB (0.50) | ACACBCALCACALCRL | |
| SCHEMBL137686 | 0.93 | ACACB (0.48) | ACACBCALCACALCRL | |
| SCHEMBL178752 | 0.81 | ALDH1A1 (0.49) | ACACBCALCA | |
| SCHEMBL23564698 | 0.81 | ALDH1A1 (0.49) | ACACBCALCA | |
| SCHEMBL31628221 | 0.81 | ALDH1A1 (0.49) | ACACBCALCA | |
| SCHEMBL3353834 | 0.77 | CALCA (0.41) | CALCACALCRL | |
| SCHEMBL3353840 | 0.77 | CALCA (0.41) | CALCACALCRL | |
| SCHEMBL139773 | 0.77 | POLB (0.46) | — | |
| SCHEMBL4500163 | 0.76 | CTSL (0.50) | — | |
| SCHEMBL140133 | 0.76 | SLC7A5 (0.42) | CALCACALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4284505-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | Pfizer Ireland Pharmaceuticals (IE) | 2023-12-06 | — | — | EP | disclosed |
| US-20220401439-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2022-12-22 | — | — | US | disclosed |
| EP-4076395-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-114980862-A | Intranasal pharmaceutical compositions of CGRP inhibitors | 拜尔哈文制药股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021127070-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-2552906-B1 | CGRP RECEPTOR ANTAGONIST | BRISTOL MYERS SQUIBB CO (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8481546-B2 | CGRP receptor antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2552906-A1 | CGRP RECEPTOR ANTAGONIST | Bristol-Myers Squibb Company (US) | 2013-02-06 | — | — | EP | disclosed |
| US-20120059017-A1 | CGRP Receptor Antagonist | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| WO-2011123232-A1 | CGRP RECEPTOR ANTAGONIST | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-06 | — | — | WO | disclosed |
| US-7834007-B2 | CGRP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-16 | — | — | US | disclosed |
| US-7569578-B2 | Heterocyclic anti-migraine agents | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2009-08-04 | — | — | US | disclosed |
| US-7449586-B2 | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070049577-A1 | CGRP antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
| EP-1689738-A2 | HETEROCYCLIC ANTI-MIGRAINE AGENTS | Bristol-Myers Squibb Company (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2006060678-A2 | NOVEL PROCESSES FOR THE PREPARATION OF CGRP-RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060122250-A1 | Novel processes for the preparation of CGRP-receptor antagonists and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-08 | — | — | US | disclosed |
| US-20050153959-A1 | 3-{1-[4-(7-Methyl-1H-indazol-5-yl)-3-pyridin-2-yl-butyryl]-piperidin-4-yl}-3,4-dihydro-1H-quinazolin-2-one; small molecule; non-peptidic; antagonists of calcitonin gene-related peptide receptors (\"CGRP-receptor\"); neurogenic vasodilation and inflammation, cluster headache | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-14 | — | — | US | disclosed |
| WO-2005056550-A2 | HETEROCYCLIC ANTI-MIGRAINE AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401439-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | CALCA, CALCB, CALCRL | ACACB 3361/4885CALCA 1/4885CALCRL 3/4885 |
| US-20070049577-A1 | CGRP antagonists | CALCRL, CALCR, CALCA | ACACB 3244/4885CALCA 3/4885CALCRL 1/4885 |
| US-20050153959-A1 | 3-{1-[4-(7-Methyl-1H-indazol-5-yl)-3-pyridin-2-yl-butyryl]-piperidin-4-yl}-3,4-dihydro-1H-quinazolin-2-one; small molecule; non-peptidic; antagonists of calcitonin gene-related peptide receptors (\"CGRP-receptor\"); neurogenic vasodilation and inflammation, cluster headache | CALCRL, CALCA, BDKRB2 | ACACB 2498/4885CALCA 2/4885CALCRL 1/4885 |
| US-20060122250-A1 | Novel processes for the preparation of CGRP-receptor antagonists and intermediates thereof | CALCR, CALCRL, CALCB | ACACB 3951/4885CALCA 4/4885CALCRL 2/4885 |
| US-20120059017-A1 | CGRP Receptor Antagonist | CALCRL, PTGIR, CALCR | ACACB 3777/4885CALCA 7/4885CALCRL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.